White House Press Secretary Karoline Leavitt has confirmed that President Donald Trump's announcement, scheduled for 13:00ET/18:00GMT is related to pharmaceuticals. In the past 24 hours, reports from Axios and Reuters suggest that Trump could announce a deal with pharma giants to lower prescription drug prices under the 'most favoured nation' (MFN) regulation. Bloomberg reported on 17 Dec that agreements with Swiss giants Novartis and Roche had been reached, with Reuters reporting AbbVie may be another of the estimated five new firms to sign up.
Find more articles and bullets on these widgets:
What's notable about the majority of post-shutdown rescheduled economic releases so far is that they are essential to compiling advance Q3 GDP and September PCE, both of which were originally due to be published by the Bureau of Economic Analysis at the end of October.

S&P E-Minis maintain a softer short-term tone. The breach of support at 6655.70, the Nov 7 low cancels recent bullish signals and signals scope for an extension of the current corrective cycle. Note that price has also breached support at the 50-day EMA. An extension would open 6540.25, the Oct 10 low and the next key support. Initial firm resistance to watch is 6779.00, the 20-day EMA.
